Bomedemstat dihydrochloride

• CAT Number: I041434
• Molecular Formula: C28H36Cl2FN7O2
• Molecular Weight: 592.54
• Purity: ≥95%
• Synonyms: N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide;dihydrochloride
• InChI: InChI=1S/C28H34FN7O2.2ClH/c1-34-15-17-35(18-16-34)28(38)25(3-2-12-30-26-19-24(26)20-4-8-22(29)9-5-20)32-27(37)21-6-10-23(11-7-21)36-14-13-31-33-36;;/h4-11,13-14,24-26,30H,2-3,12,15-19H2,1H3,(H,32,37);2*1H/t24-,25-,26+;;/m0../s1
• InChIKey: PPKDUCDLYRHGFX-DVNXTAPYSA-N
• SMILES: CN1CCN(CC1)C(=O)[C@H](CCCN[C@@H]2C[C@H]2C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)N5C=CN=N5.Cl.Cl

Bomedemstat dihydrochloride（Cat No.:I041434）is a potent, selective inhibitor of the lysine-specific demethylase 1 (LSD1), an enzyme implicated in the regulation of gene expression. By inhibiting LSD1, Bomedemstat dihydrochloride demonstrates potential therapeutic activity in various cancers, particularly those with aberrant epigenetic regulation. It has shown promise in clinical trials, particularly for hematologic malignancies like acute myeloid leukemia (AML). This compound’s ability to modulate transcription factors and chromatin remodeling highlights its importance in cancer therapy, inflammation, and immunology, offering a novel approach for targeted epigenetic treatment strategies.